Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

BACKGROUND: Skin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Leiter, Ulrike, Loquai, Carmen, Reinhardt, Lydia, Rafei-Shamsabadi, David, Gutzmer, Ralf, Kaehler, Katharina, Heinzerling, Lucie, Hassel, Jessica C, Glutsch, Valerie, Sirokay, Judith, Schlecht, Nora, Rübben, Albert, Gambichler, Thilo, Schatton, Kerstin, Pfoehler, Claudia, Franklin, Cindy, Terheyden, Patrick, Haferkamp, Sebastian, Mohr, Peter, Bischof, Lena, Livingstone, Elisabeth, Zimmer, Lisa, Weichenthal, Michael, Schadendorf, Dirk, Meiwes, Andreas, Keim, Ulrike, Garbe, Claus, Becker, Jürgen Christian, Ugurel, Selma
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7583786/
https://ncbi.nlm.nih.gov/pubmed/33093156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000897
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky